PT1073738E - Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas - Google Patents

Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas

Info

Publication number
PT1073738E
PT1073738E PT99920731T PT99920731T PT1073738E PT 1073738 E PT1073738 E PT 1073738E PT 99920731 T PT99920731 T PT 99920731T PT 99920731 T PT99920731 T PT 99920731T PT 1073738 E PT1073738 E PT 1073738E
Authority
PT
Portugal
Prior art keywords
nucleic acid
methods
present
ion channel
relates
Prior art date
Application number
PT99920731T
Other languages
English (en)
Inventor
Pardo-Fernandez Luis Angel
Stuehmer Walter
Beckh Synnoeve
Brueggemann Andrea
Del Camino Fernandez-Mi Donato
Sanchez Perez Araceli
Weseloh Ruediger
Original Assignee
Max Planck Ges Forderung Der W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Ges Forderung Der W filed Critical Max Planck Ges Forderung Der W
Publication of PT1073738E publication Critical patent/PT1073738E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99920731T 1998-04-21 1999-04-21 Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas PT1073738E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98107268 1998-04-21

Publications (1)

Publication Number Publication Date
PT1073738E true PT1073738E (pt) 2005-01-31

Family

ID=8231794

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99920731T PT1073738E (pt) 1998-04-21 1999-04-21 Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas

Country Status (10)

Country Link
US (7) US6638736B1 (pt)
EP (1) EP1073738B1 (pt)
JP (2) JP2002512029A (pt)
AT (1) ATE278017T1 (pt)
CA (1) CA2323571A1 (pt)
DE (1) DE69920681T2 (pt)
DK (1) DK1073738T3 (pt)
ES (1) ES2230852T3 (pt)
PT (1) PT1073738E (pt)
WO (1) WO1999054463A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1073738T3 (da) * 1998-04-21 2005-01-24 Max Planck Gesellschaft Human K+-ionkanal og terapeutiske applikationer deraf
DE10025620A1 (de) * 2000-05-24 2001-12-06 Forschungsgesellschaft Genion Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten
DE10224534A1 (de) 2002-05-31 2003-12-11 Juergen Dolderer Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung
ATE497508T1 (de) * 2004-10-01 2011-02-15 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
MX2007003865A (es) * 2004-10-01 2009-06-17 Ct Investig Y Estudios Del Ipn Métodos para el diagnóstico temprano de infecciones virales y enfermedades inflamatorias o de la predisposición de un individuo a desórdenes proliferativos o hiperplasia.
AU2013201604B2 (en) * 2007-04-13 2014-08-14 Southern Research Institute Anti-angiogenic agents and methods of use
ES2334084B1 (es) * 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
TWI570415B (zh) * 2015-10-02 2017-02-11 A spring probe having an outer sleeve and a probe device having the spring probe
EP3195727A1 (en) 2016-01-22 2017-07-26 Forschungsinstitut Fur Biologischen Landbau (FiBL) Duddingtonia flagrans strain and feed additive formulation for biological pest control

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
AU665341B2 (en) 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
AU3440697A (en) * 1996-07-02 1998-01-21 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
US6610827B1 (en) * 1997-10-29 2003-08-26 Elan Pharmaceuticals, Inc. Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
DK1073738T3 (da) * 1998-04-21 2005-01-24 Max Planck Gesellschaft Human K+-ionkanal og terapeutiske applikationer deraf

Also Published As

Publication number Publication date
US20030092120A1 (en) 2003-05-15
JP2009235091A (ja) 2009-10-15
US20030087378A1 (en) 2003-05-08
US7314914B2 (en) 2008-01-01
US20080020406A1 (en) 2008-01-24
EP1073738B1 (en) 2004-09-29
JP2002512029A (ja) 2002-04-23
US7129207B2 (en) 2006-10-31
DE69920681T2 (de) 2005-09-08
US7364845B2 (en) 2008-04-29
DE69920681D1 (de) 2004-11-04
US20100021467A1 (en) 2010-01-28
US20030077735A1 (en) 2003-04-24
WO1999054463A3 (en) 2000-04-20
ES2230852T3 (es) 2005-05-01
CA2323571A1 (en) 1999-10-28
US7364730B2 (en) 2008-04-29
US6638736B1 (en) 2003-10-28
US20030087377A1 (en) 2003-05-08
WO1999054463A2 (en) 1999-10-28
ATE278017T1 (de) 2004-10-15
EP1073738A2 (en) 2001-02-07
DK1073738T3 (da) 2005-01-24

Similar Documents

Publication Publication Date Title
Zhu et al. Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition
Nakatsuji et al. A commensal strain of Staphylococcus epidermidis protects against skin neoplasia
Beug et al. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
Dmytriyeva et al. The metastasis-promoting S100A4 protein confers neuroprotection in brain injury
Li et al. Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin
BR0312913A (pt) Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
Namyen et al. Protective effects of melatonin on methamphetamine-induced blood–brain barrier dysfunction in rat model
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
Hou et al. The inhibitory effect of IFN-γ on protease HTRA1 expression in rheumatoid arthritis
DE60028970D1 (de) An her2 bindende peptidverbindungen
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
Shou et al. Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells
Lv et al. Scutellarin inhibits hypoxia‐induced epithelial‐mesenchymal transition in bladder cancer cells
PT1073738E (pt) Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas
Ma et al. Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury
Lu et al. P2X 7 signaling promotes microsphere embolism-triggered microglia activation by maintaining elevation of Fas ligand
Jo et al. Tat-HSP22 inhibits oxidative stress-induced hippocampal neuronal cell death by regulation of the mitochondrial pathway
Philipp et al. Radiation-induced endothelial inflammation is transferred via the secretome to recipient cells in a STAT-mediated process
BR0215063A (pt) Derivados de hidroxifenil-pirazol ativos como inibidores de cinase, processo para preparação dos mesmos e composições farmacêuticas compreendendo-os
Li et al. USP21 regulates Hippo signaling to promote radioresistance by deubiquitinating FOXM1 in cervical cancer
Ahmed et al. Combinatory effects of bone marrow-derived mesenchymal stem cells and indomethacin on adjuvant-induced arthritis in Wistar rats: roles of IL-1β, IL-4, Nrf-2, and oxidative stress
Behrens et al. Lipocalin 2 as a putative modulator of local inflammatory processes in the spinal cord and component of organ cross talk after spinal cord injury
Jiang et al. Enolase1 alleviates cerebral ischemia-induced neuronal injury via its enzymatic product phosphoenolpyruvate